R & D

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

 This material is intended to notify the press release issued on February 28 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.